Posted by Adam Awdish on
Pooled Human Serum Off The Clot from Innovative Research was used in the following study:
Lorena Vigón, Javier García-Pérez, Sara Rodríguez-Mora, Montserrat Torres, Elena Mateos, María Castillo de la Osa, Miguel Cervero, Rosa Malo De Molina, Cristina Navarro, María Aránzazu Murciano-Antón, Valentín García-Gutiérrez, Vicente Planelles, José Alcamí, Mayte Pérez-Olmeda, Mayte Coiras and María Rosa López-Huertas
Frontiers in Immunology
September 20, 2021
Clinical symptoms of COVID-19 infection can range anywhere from asymptomatic to severe, even fatal, infections caused by the cytokine storm elicited by the innate immune response. As such, patients with severe COVID-19 infections have been found to have high levels of inflammation markers in their plasma, such as IL-6, ferritin, or CRP. Patients with extremely severe cases, however, have shown low levels of antiviral cytokines, such as IL-2 and IL-12.
In general, among all patients, there is typically an increase in specific memory B cells that target SARS-CoV-2 during the first few months following infection. In theory, this could provide some immunity toward the infection, even in antibody concentrations decline, however, there is not much data in existence to support this claim. In this study, researchers analyzed the immune responses of patients with COVID-19, ranging from mild to critical cases, and quantified their innate immune responses to the infection.
Related products available from Innovative Research also include: